ProfileGDS5678 / 1436399_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 49% 48% 50% 49% 48% 48% 53% 58% 49% 48% 51% 50% 52% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2003349
GSM967853U87-EV human glioblastoma xenograft - Control 23.1386148
GSM967854U87-EV human glioblastoma xenograft - Control 33.1882850
GSM967855U87-EV human glioblastoma xenograft - Control 43.0989449
GSM967856U87-EV human glioblastoma xenograft - Control 53.0777148
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2466848
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3818653
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5069558
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1341949
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1226348
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2175651
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1611150
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2829552
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1608649